Cord Blood Transplant for Blood Cancers
Trial Summary
What is the purpose of this trial?
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor to get specific guidance.
What data supports the effectiveness of this treatment for blood cancers?
Research shows that umbilical cord blood transplantation (using stem cells from umbilical cord blood) is a promising treatment for blood cancers, especially when other treatments have failed. It has advantages like better matching and lower risk of complications compared to other stem cell sources, and studies have shown it can lead to better disease control and survival rates.12345
Is cord blood transplant generally safe for humans?
Cord blood transplants, like other stem cell transplants, can have serious side effects, but recent advances have made them less toxic. Studies show that using less intense conditioning treatments can reduce complications, although some risks remain, such as infections and organ-related side effects.678910
How is cord blood transplant treatment different from other treatments for blood cancers?
Cord blood transplant treatment is unique because it uses stem cells from umbilical cord blood, which can be a suitable option for patients who do not have a matched donor in their family or the unrelated registry. This approach can reduce the risk of severe graft-versus-host disease and is particularly beneficial for patients from diverse ethnic backgrounds who may struggle to find a fully matched donor.311121314
Eligibility Criteria
This trial is for adults with various high-risk blood cancers, including different types of leukemia and lymphoma. Participants must meet specific criteria such as being in a certain phase of remission, having adequate organ function, and not having had certain previous treatments like stem cell transplants within the last year.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Conditioning Treatment
Participants receive standard chemotherapy and total body irradiation therapy to prepare for the transplant
Transplantation
Infusion of the double-unit cord blood graft
Post-Transplant Monitoring
Participants are monitored for side effects, disease relapse, GVHD, and immune system recovery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Conditioning Chemotherapy (Chemotherapy)
- Cord blood graft (Stem Cell Transplant)
Conditioning Chemotherapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Blood cancers
- Leukemia
- Lymphoma
- Multiple myeloma
- Blood cancers
- Leukemia
- Lymphoma
- Multiple myeloma
- Blood cancers
- Leukemia
- Lymphoma
- Multiple myeloma
- Blood cancers
- Leukemia
- Lymphoma
- Multiple myeloma
- Blood cancers
- Leukemia
- Lymphoma
- Multiple myeloma
- Blood cancers
- Leukemia
- Lymphoma
- Multiple myeloma